Dashboard Tools Market News Investing Ideas Pricing
Search 100,000+ stocks...
English EN
Deutsch DE Español ES
Sign Up
Log in
Lineage Cell Therapeutics Inc banner
L

Lineage Cell Therapeutics Inc
F:BT3

Watchlist Manager
Lineage Cell Therapeutics Inc
F:BT3
Watchlist
Price: 0.862 EUR -5.38% Market Closed
Market Cap: €162.7m
Write Note Create Alert Ask AI

Wall St Price Targets

BT3 Price Targets Summary
Lineage Cell Therapeutics Inc

Wall Street analysts forecast BT3 stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for BT3 is 4.875 EUR with a low forecast of 2.633 EUR and a high forecast of 8.212 EUR.

BT3 Lowest Forecast
Wall Street Target
€2.633
205% Upside
BT3 Average Forecast
Wall Street Target
€4.875
466% Upside
BT3 Highest Forecast
Wall Street Target
€8.212
853% Upside
Lowest Forecast
Price Target
2.633 EUR
205% Upside
Average Forecast
Price Target
4.875 EUR
466% Upside
Highest Forecast
Price Target
8.212 EUR
853% Upside
Lineage Cell Therapeutics Inc Competitors:
Price Targets
V
VERK
Verkkokauppa.com Oyj
16% Upside
CENT
Central Garden & Pet Co
32% Upside
LAND
Gladstone Land Corp
6% Upside
V
VERK
Verkkokauppa.com Oyj
16% Upside
CENT
Central Garden & Pet Co
32% Upside
LAND
Gladstone Land Corp
6% Upside

Revenue
Forecast

53% / Year
Past Growth
74% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
53% / Year
Past Growth
74% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

Over the last 1 year, the compound annual growth rate for Revenue has been 53%. The projected CAGR for the next 8 years is 74%.

What are analyst estimates?

Gross Profit
Forecast

57% / Year
Past Growth
74% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
57% / Year
Past Growth
74% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

Over the last 1 year, the compound annual growth rate for Gross Profit has been 57%. The projected CAGR for the next 8 years is 74%.

What are analyst estimates?

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

What are analyst estimates?

Pre-Tax Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

What are analyst estimates?

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

What are analyst estimates?

Continue BT3 Research

Summary
BT3 intrinsic value, competitors valuation, and company profile.
DCF Valuation
BT3 stock valuation using Discount Cash Flow valuation method.
Relative Valuation
BT3 stock valuation using valuation multiples.
Wall St Estimates
BT3 price targets and financial estimates made by Wall Street analysts.
Profitability
Detailed analysis of the company's profitability.
Solvency
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
BT3 stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall St Estimates
Profitability
Solvency
Financials
Discount Rate
Other Lineage Cell Therapeutics Inc listings:
XBER • EUR
BT3
 TASE • ILS
LCTX
 AMEX • USD
LCTX
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is BT3's stock price target?
Price Target
4.875 EUR

According to Wall Street analysts, the average 1-year price target for BT3 is 4.875 EUR with a low forecast of 2.633 EUR and a high forecast of 8.212 EUR.

What is the Revenue forecast for Lineage Cell Therapeutics Inc?
Projected CAGR
74%

Over the last 1 year, the compound annual growth rate for Revenue has been 53%. The projected CAGR for the next 8 years is 74%.

What is the Gross Profit forecast for Lineage Cell Therapeutics Inc?
Projected CAGR
74%

Over the last 1 year, the compound annual growth rate for Gross Profit has been 57%. The projected CAGR for the next 8 years is 74%.

Back to Top
ALPHA SPREAD
Follow us
Join 357,200+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Valuation Backtest Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.

AI Assistant
Get AI-powered insights for any company or topic.
Open AI Assistant
Other Tools
Stock Screener
Discover stocks
Stock Comparison
Smarter decisions through side-by-side analysis
Intrinsic Value Calculator
Discover the true worth of your stocks
DCF Value Calculator
Harness the power of DCF

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett